The latest version of the NCCN Guidelines has just been published. It takes a free registration to access the guideline. This link is to a pdf of the physician's version.NCCN Guidelines Version 1.2019 - Prostate Cancer
There's a lot in there. Just a couple of observations related to the high/very high risk cases:
They modified the ADT duration for EBRT + ADT to 1.5- 3 years (was 2-3 years), recognizing studies showing shorter durations seem to be effective.
They have removed the footnote about
adding 6 cycles of Docetaxel after RT, so i guess that's not a recommendation anymore.
55@Dx on 4/16/13. PSA 5.2, G9(5+4), PNI+, cT3a by MRI.
IGRT - 44 sessions (79.2 Gy, 50.4 Gy pelvic)
ADT2 - Lupron+Casodex (5/13-3/16)
8/13-5/16 <0.1 (ADT2)
5/16-3/17 recovering from ADT2
3/17-12/18 up and down ~ 0.6 - 1.0 (no TX)
latest 3/19 = 0.7My Story